The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

BACKGROUND: Rivastigmine is the only cholinesterase inhibitor (ChEI) available as transdermal patch. The patch was developed to improve gastrointestinal tolerability and treatment adherence to higher dosages as compared with oral medication. Preferences of patients and caregivers for the patch were...

Descripción completa

Detalles Bibliográficos
Autores principales: Adler, G, Mueller, B, Articus, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237461/
https://www.ncbi.nlm.nih.gov/pubmed/24588972
http://dx.doi.org/10.1111/ijcp.12374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237461/
https://www.ncbi.nlm.nih.gov/pubmed/24588972
http://dx.doi.org/10.1111/ijcp.12374

Ejemplares similares